<DOC>
	<DOCNO>NCT00076349</DOCNO>
	<brief_summary>SUMMARY : This open label study combine Rituxan SDX-105 . Rituxan give day 1 follow 30-60 minute intravenous infusion SDX-105 day 2 day 3 . Treatment repeat every 21 day ( cycle ) . Treatment continue 6 cycle ( 4 month ) tumor status improve unacceptable side effect . Patients follow 2 year disease progression . RATIONALE : Rituxan show increase sensitivity cell chemotherapy . The combination SDX-105 Rituxan effective laboratory recent clinical study Non-Hodgkin 's lymphoma patient . PURPOSE : This study evaluate safety effectiveness SDX-105 plus Rituxan patient Non-Hodgkin 's lymphoma relapse take Rituxan .</brief_summary>
	<brief_title>SDX-105 Combination With Rituxan Patients With Relapsed Indolent Mantle Cell Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>INCLUSION CRITERIA : Documented BCell NHL mantle cell lymphoma CD20+ tumor Indolent NHL : follicular Bcell lymphoma , diffuse small lymphoma , marginal zone lymphoma Maximum three prior chemotherapy regimens Age least 18 year Screening Visit ( Site specific requirement may differ ) EXCLUSION CRITERIA : Refractory rituximab , define progression disease treat rituximab progression within 6 month last dose rituximab ( give either single agent combination ) Previous chemotherapy immunotherapy within 3 week prior enter study ( 6 week nitrosoureas mitomycin ) failure recover adverse event due agent administer previously Use investigational agent within 28 day study History prior high dose chemotherapy allogeneic stem cell support History prior radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Mantle Cell</keyword>
	<keyword>mabs</keyword>
</DOC>